Business Wire

ADVA

30.4.2020 09:02:05 CEST | Business Wire | Press release

Share
dacoso secures VPN with ADVA ConnectGuard™ Cloud encryption

ADVA (FSE: ADV) today announced that dacoso has deployed its ConnectGuard™ Cloud encryption solution for robust software-based network protection. By leveraging the industry-first cloud-native technology, the IT service provider is ensuring end-to-end security for its virtual private network (VPN). The cost-effective and low-latency solution is now safeguarding connectivity between dacoso’s data centers in Germany, Austria and Switzerland, as well as its virtual cloud services. The deployment improves dacoso’s bandwidth efficiency while complying with all relevant industry standards. Also, by moving to a cloud-native security solution, dacoso’s mission-critical network benefits from enhanced flexibility and cost-efficiency.

“By deploying ADVA’s ConnectGuard™ Cloud technology, we’re harnessing virtualized encryption that’s flexible, scalable and doesn’t come with a heavy bandwidth penalty. The solution ensures rigorous data protection for both our branches and our cloud locations. And, because it works without large additional data ballast, it also improves network utilization and reduces cost-per-encrypted-bit,” said Karsten Geise, head of business and product development, dacoso. “Now our cloud network meets all regulatory requirements, such as GDPR, while being simpler and more efficient. Removing the need for hardware appliances also frees up valuable rack space and means we can easily shop around for new innovation in the future rather than being constrained by single-vendor lock-in.”

dacoso provides managed services for businesses that rely on the highest levels of security, including virtual environments. As hardware-based encryption isn’t possible in cloud provider data centers, the software-based protection that ConnectGuard™ Cloud offers is vital. Based on ADVA’s industry-leading Ensemble Connector virtualization platform, the solution delivers a host of benefits. These include end-to-end encryption at Layer 2, 3 and 4, along with improved latency and throughput performance compared to IPSec. With its zero-touch provisioning and automated key management, ADVA’s unique cloud-native technology also significantly simplifies operations for dacoso’s team. Complexity is further reduced by automated key distribution and management, centrally orchestrated by the ADVA Ensemble Controller management solution.

“dacoso now has all the advantages of highly efficient and extremely rigorous encryption, delivered entirely through software. That means ultra-low latency protection at Layers 2, 3 and 4, as well as unrivaled advantages in terms of scale and ease of use,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “ConnectGuard™ Cloud really is the ultimate solution for site-to-site and site-to-cloud encrypted VPNs. It’s also the perfect fit for dacoso’s needs. With transport-layer independent security, they can rely on comprehensive protection that won’t affect the performance of the services it provides. What’s more, as part of our Ensemble portfolio of open NFV solutions, ConnectGuard™ Cloud unshackles dacoso from vendor lock-in and offers freedom to mix and match new technologies in the future.”


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About dacoso
dacoso offers solutions for Connectivity, Cyber Security and Virtual Networking. The IT service provider thereby addresses companies that need their data to be highly available and secure yet without sacrificing agility. dacoso services comprise, among other, optical data links encrypted to satisfy BSI, a certified Security Operation Center, Managed Security Services and virtualization solutions to increase the dynamic performance of networks. dacoso GmbH is an owner-managed company headquartered in Langen, Frankfurt a.M., with a further 11 locations in Germany, Austria and Switzerland. www.dacoso.com

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye